AbbVie

AbbVie and Iambic announced a multi-year collaboration using Iambic's AI discovery platform to find small-molecule candidates in immunology, neuroscience and oncology.

Partners: Iambic

AbbVie and BigHat announced a research collaboration using BigHat's AI/ML-guided Milliner platform to discover next-generation antibodies in oncology and neuroscience, with a $30 million upfront payment.

Partners: BigHat Biosciences

AbbVie says AI is used daily in its manufacturing operations, including predictive equipment information and guiding robotics and automation with real-time shop-floor data.

AbbVie is piloting WRAP, a Whole Room AI Platform intended to act as a digital twin so factory staff can verify a manufacturing space meets required standards before operations begin.

AbbVie uses AI- and ML-powered analytics on decades of historical data to predict which clinical trial sites will activate quickly.

AbbVie says large language models let researchers engineer drug candidates in silico rather than relying solely on high-throughput screening.

AbbVie's ARCH platform centralizes R&D data and hosts chemists' predictive models, which AbbVie says are rerun on 30-day cycles; AbbVie also says its generative AI platform is being embedded into ARCH.